Skip to main content

Advertisement

SpringerLink
Log in

Comprehensive investigation of aberrant microRNA profiling in bladder cancer tissues

  • Published:
Tumor Biology

Abstract

There has been accumulative evidence that microRNAs (miRNAs) play essential roles in the tumorigenesis and progression of bladder cancer. However, individual studies and small sample size caused discrepant outcomes. Thus, the current study focused on a comprehensive profiling of all differentially expressed miRNAs in a total of 519 bladder cancer tissue samples, based on miRNA microarray data. Altogether, 11 prioritized miRNAs stated by 21 published microarray datasets, including five down-regulated (miR-133a-3p, miR-1-3p, miR-99a-5p, miR-490-5p, and miR-133b) and six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171) were analyzed with vote-counting strategy and a Robust Rank Aggregation method. Subsequently, miRNA in silico target prediction and potential pathway enrichment analysis were performed to investigate the prospective molecular mechanism of miRNAs in the tumorigenesis of bladder cancer. We found that most of the relative pathways of the aberrantly expressed miRNAs found in the current study were closely correlated with different biological processes, cellular components, molecular functions, cancer pathogeneses, and some cell signalings, such as Wnt signaling, insulin/IGF, PI3 kinase, and FGF signaling pathways. Hence, a comprehensive overview on the miRNA expression pattern in bladder cancer tissues was gained by the current study. These miRNAs might be involved in the tumorigenesis and deterioration of bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1
Fig 2
Fig 3
Fig 4
Fig 5
Fig 6
Fig 7

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer J Int Cancer. 2015;136(5):E359–86.

    Article  CAS  Google Scholar 

  2. Miremami J, Kyprianou N. The promise of novel molecular markers in bladder cancer. Int J Mol Sci. 2014;15(12):23897–908.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol. 2014;32(2):353–8.

    Article  CAS  PubMed  Google Scholar 

  4. Wang Z, Cai Q, Jiang Z, Liu B, Zhu Z, Li C: Prognostic role of microRNA-21 in gastric cancer: a meta-analysis. Med Sci Monit Int Med J Exp Clin Res 2014, 20:1668–1674.

  5. Chen QW, Zhu XY, Li YY, Meng ZQ. Epigenetic regulation and cancer (review). Oncol Rep. 2014;31(2):523–32.

    PubMed  Google Scholar 

  6. Jin D, Fang Y, Li Z, Chen Z, Xiang J. Epithelial-mesenchymal transitionassociated microRNAs in colorectal cancer and drug-targeted therapies (review). Oncol Rep. 2015;33(2):515–25.

    CAS  PubMed  Google Scholar 

  7. Lyra-Gonzalez I, Flores-Fong LE, Gonzalez-Garcia I, Medina-Preciado D, Armendariz-Borunda J. MicroRNAs dysregulation in hepatocellular carcinoma: insights in genomic medicine. World J Hepatol. 2015;7(11):1530–40.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Zhu W, Xu B. MicroRNA-21 identified as predictor of cancer outcome: a meta-analysis. PLoS One. 2014;9(8):e103373.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Pan F, Mao H, Deng L, Li G, Geng P. Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. Int J Clin Exp Pathol. 2014;7(9):5622–33.

    PubMed  PubMed Central  Google Scholar 

  10. Zheng RL, Jiang YJ, Wang X. Role of microRNAs on therapy resistance in non-Hodgkin’s lymphoma. Int J Clin Exp Med. 2014;7(11):3818–32.

    PubMed  PubMed Central  Google Scholar 

  11. Kozomara A. Griffiths-Jones S: miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42(Database issue):D68–73.

    Article  CAS  PubMed  Google Scholar 

  12. Ding M, Li Y, Wang H, Lv Y, Liang J, Wang J, Li C. Diagnostic value of urinary microRNAs as non-invasive biomarkers for bladder cancer: a meta-analysis. Int J Clin Exp Med. 2015;8(9):15432–40.

    PubMed  PubMed Central  Google Scholar 

  13. Chen L, Cui Z, Liu Y, Bai Y, Lan F. MicroRNAs as biomarkers for the diagnostics of bladder cancer: a meta-analysis. Clin Lab. 2015;61(8):1101–8.

    CAS  PubMed  Google Scholar 

  14. Ouyang H, Zhou Y, Zhang L, Shen G. Diagnostic value of MicroRNAs for urologic cancers: a systematic review and meta-analysis. Medicine. 2015;94(37):e1272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cheng Y, Deng X, Yang X, Li P, Zhang X, Li P, Tao J, Lu Q, Wang Z. Urine microRNAs as biomarkers for bladder cancer: a diagnostic meta-analysis. OncoTargets Ther. 2015;8:2089–96.

    Google Scholar 

  16. Shi Z, Wei Q, Zhang M, She J. MicroRNAs in bladder cancer: expression profiles, biological functions, regulation, and clinical implications. Crit Rev Eukaryot Gene Expr. 2014;24(1):55–75.

    Article  CAS  PubMed  Google Scholar 

  17. Zhou H, Tang K, Xiao H, Zeng J, Guan W, Guo X, Xu H, Ye Z. A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res CR. 2015;34:53.

    Article  PubMed  Google Scholar 

  18. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer J Int Cancer. 2009;125(2):345–52.

    Article  CAS  Google Scholar 

  19. Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, Li H. Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev: APJCP. 2010;11(4):905–11.

    PubMed  Google Scholar 

  20. Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N, Nakagawa M. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer. 2011;104(5):808–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Yamasaki T, Yoshino H, Enokida H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Fuse M, Seki N, Nakagawa M. Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol. 2012;40(6):1821–30.

    CAS  PubMed  Google Scholar 

  22. Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B. Amsellem-Ouazana D et al: microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer J Int Cancer. 2013;132(11):2479–91.

    Article  CAS  Google Scholar 

  23. Wang T, Yuan J, Feng N, Li Y, Lin Z, Jiang Z, Gui Y. Hsa-miR-1 downregulates long non-coding RNA urothelial cancer associated 1 in bladder cancer. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35(10):10075–84.

    Article  CAS  Google Scholar 

  24. Du M, Shi D, Yuan L, Li P, Chu H, Qin C, Yin C, Zhang Z, Wang M. Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. Sci Report. 2015;5:10437.

    Article  Google Scholar 

  25. Yoshino H, Enokida H, Chiyomaru T, Tatarano S, Hidaka H, Yamasaki T, Gotannda T, Tachiwada T, Nohata N, Yamane T, et al. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Biochem Biophys Res Commun. 2012;417(1):588–93.

    Article  CAS  PubMed  Google Scholar 

  26. Feng Y, Kang Y, He Y, Liu J, Liang B, Yang P. Yu Z: microRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer. BMC Urol. 2014;14:50.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Zhang DZ, Lau KM, Chan ES, Wang G, Szeto CC, Wong K, Choy RK, Ng CF. Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS One. 2014;9(7):e100793.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Xu Z, Yu YQ, Ge YZ, Zhu JG, Zhu M, Zhao YC, Xu LW, Yang XB, Geng LG, Dou QL, et al. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival. Tumour Biol J Int Soc Oncodev Biol Med. 2015;36(10):8159–66.

    Article  CAS  Google Scholar 

  29. Wu D, Zhou Y, Pan H, Zhou J, Fan Y. Qu P: microRNA-99a inhibiting cell proliferation, migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer. Oncol Lett. 2014;7(4):1219–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Lan G, Yang L, Xie X, Peng L, Wang Y. MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in human bladder cancer. Arch Med Sci AMS. 2015;11(3):561–9.

    Article  PubMed  Google Scholar 

  31. Li S, Xu X, Xu X, Hu Z, Wu J, Zhu Y, Chen H, Mao Y, Lin Y, Luo J, et al. MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos. Biochem Biophys Res Commun. 2013;441(4):976–81.

    Article  CAS  PubMed  Google Scholar 

  32. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, Jiang Z, Zhang Z, Yang R, Chen J, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One. 2011;6(3):e18286.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Chen XN, Wang KF, Xu ZQ, Li SJ, Liu Q, Fu DH, Wang X, Wu B. MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int. 2014;14:70.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69(11):4851–60.

    Article  CAS  PubMed  Google Scholar 

  35. Zhou Y, Wu D, Tao J, Qu P, Zhou Z, Hou J. MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol. 2013;47(5):423–32.

    Article  CAS  PubMed  Google Scholar 

  36. Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin C. Zhang W: microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep. 2012;27(6):1967–75.

    CAS  PubMed  Google Scholar 

  37. Kriebel S, Schmidt D, Holdenrieder S, Goltz D, Kristiansen G, Moritz R, Fisang C, Muller SC, Ellinger J. Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer. PLoS One. 2015;10(1):e0117284.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R. Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One. 2012;7(11):e51056.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mengual L, Lozano JJ, Ingelmo-Torres M, Gazquez C, Ribal MJ, Alcaraz A. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer J Int Cancer. 2013;133(11):2631–41.

    CAS  Google Scholar 

  40. Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, Qu A, Zhang X, Pan H, Yang Y, et al. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer J Int Cancer. 2015;136(4):854–62.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Genomic and Personalized Medicine, Guangxi Medical University, 22 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China

    Yanping Wei, Rongquan He, Gang Chen, Qiuyan Wang, Xinggu Lin, Yingchun Chen & Zengnan Mo

  2. Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China

    Yuzhuang Wu, Binliang Gan, Peirong Wu, Xiaohui Qiu, Aihua Lan & Gang Chen

  3. Department of Urology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China

    Zengnan Mo

Authors
  1. Yanping Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rongquan He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuzhuang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Binliang Gan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peirong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaohui Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aihua Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Qiuyan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xinggu Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yingchun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zengnan Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xinggu Lin or Yingchun Chen.

Ethics declarations

Conflicts of interest

None

Additional information

Yanping Wei and Rongquan He contributed equally as first authors, Xinggu Lin and Yingchun Chen contributed equally as corresponding authors.

The work was performed in the Center for Genomic and Personalized Medicine, Guangxi Medical University, 22 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530,021, China.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, Y., He, R., Wu, Y. et al. Comprehensive investigation of aberrant microRNA profiling in bladder cancer tissues. Tumor Biol. 37, 12555–12569 (2016). https://doi.org/10.1007/s13277-016-5121-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-5121-z

Keywords

Search

Navigation